Development and Validation of a High-Fidelity Cardiac Presurgical Planning Platform for Congenital Heart Defects Using 3D Printing Technology
- Institution
- LAZARUS 3D, INC., OR
- Principal investigator
- Tyler Kelly
- Funding
- $400K
- Duration
- 2025–2026
Moonbase score
Still being scored
Abstract
Development and Validation of a High-Fidelity Cardiac Presurgical Planning Platform for Congenital Heart Defects Using 3D Printing Technology Background: Congenital heart defects (CHD) affect 1% of infants annually, with greater risk to children born into low socioeconomic status. Many CHD are associated with high infant mortality rates such as hypoplastic left heart syndrome (HLHS), a CHD which is fatal unless treated with complex surgical interventions. By creating Pre-Sure-CHD, a patient-specific preoperative surgical rehearsal and planning platform, Lazarus 3D will facilitate rehearsal of these complex cases, improving survival rates for infants born with CHD - particularly those with low socioeconomic status. Objective: To develop and validate Pre-Sure-CHD, enhancing surgical planning and rehearsal for CHD by providing surgeons with operable, high-fidelity, patient-specific models. Methods: The study comprises three specific aims: Aim 1 involves optimizing synthetic materials to replicate the mechanical properties of cardiac tissues, ensuring realism in the Pre-Sure-CHD models. Aim 2 utilizes proprietary 3D printing technology to create patient-specific prototypes for real CHD cases, informed by CT and MRI imaging data. Aim 3 assesses the content and construct validity of Pre-Sure-CHD through surgical planning refinement, recording changes, and collecting metrics for analysis. Results: The study aims to achieve milestones, including tuning polymers to mimic cardiac tissue properties, completing Pre-Sure-CHD prototypes, and obtaining a Likert scale survey score >3.5 and a 10% improvement in surgical metrics. Conclusion: Successful completion of this project will provide the first cardiothoracic surgical rehearsal platform for CHD, empowering surgeons to optimize their approaches in a risk-free environment. Implications: Pre-Sure-CHD holds the potential to revolutionize surgical planning for critical congenital heart defects, reducing mortality rates associated with these conditions. The project's success will pave the way for a future Phase II clinical study and collaborations with medical institutions, ultimately contributing to improved patient outcomes and healthcare advancement.
LOADING MOONBASE SCORE
Questions for Lazarus 3d, Inc.
Lazarus 3d, Inc. hasn't set up its Moonbase portfolio yet, so questions about this research can't be asked here.
Related grants
Same topic, scored first.
- NIH · Michigan State University47
Oxylipin Signaling in Congenital Heart Disease
Aitor Aguirre · $434K · 2021–2026
- NIH · Health Research FoundationNot yet scored
Artificial Intelligence assisted echocardiography to facilitate optimal image extraction for congenital heart defects diagnosis in Sub-Saharan Africa
Aminkeng Zawuo Leke · $205K · 2023–2026
- NIH · Health Research FoundationNot yet scored
Artificial Intelligence assisted echocardiography to facilitate optimal image extraction for congenital heart defects diagnosis in Sub-Saharan Africa
Aminkeng Zawuo Leke · $29K · 2023–2026